Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Primary Sources
1.11. List of Abbreviations

Chapter 2. Blood Glucose Monitoring Devices Market: Executive Summary

2.1. Market Snapshot
2.2. Products and End Use Snapshots
2.3. Competitive Landscape Snapshot

Chapter 3. Blood Glucose Monitoring Devices Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising geriatric population worldwide
3.4.2. Increasing number of diabetes patients
3.4.3. Increasing awareness about diabetes preventive care
3.5. Market Restraint Analysis
3.5.1. High cost of devices
3.6. Blood Glucose Monitoring Devices Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat Of New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
3.6.3. Pricing Analysis

Chapter 4. Blood Glucose Monitoring Devices: Product Estimates & Trend Analysis

4.1. Global Blood Glucose Monitoring Market: Product Segment Dashboard
4.2. Global Blood Glucose Monitoring Devices Market by Product Outlook
4.3. Global Blood Glucose Monitoring Devices Market Size & Trend Analysis, by Product, 2023 to 2032 (USD Million)
4.4. Self-Monitoring Devices
4.4.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)
4.4.2. Blood Glucose Meter
4.4.2.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)
4.4.3. Testing Strips
4.4.3.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)
4.4.4. Lancets
4.4.4.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)
4.5. Continuous Blood Glucose Monitoring Devices
4.5.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)
4.5.2. Sensors
4.5.2.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)
4.5.3. Transmitter & Receiver
4.5.3.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)
4.5.4. Insulin Pumps
4.5.4.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)

Chapter 5. Blood Glucose Monitoring Devices: End-use Estimates & Trend Analysis

5.1. Global Blood Glucose Monitoring Market: End-use Segment Dashboard
5.2. Global Blood Glucose Monitoring Market: End-use Movement Analysis
5.3. Global Blood Glucose Monitoring Market Size & Trend Analysis, by End Use, 2023 to 2032 (USD Million)
5.4. Hospitals
5.4.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)
5.5. Homecare
5.5.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)
5.6. Diagnostics Centers
5.6.1. Market Estimates and Forecasts 2023 to 2032 (USD Million)

Chapter 6. Regional Business Analysis

6.1. Regional Market Dashboard
6.2. Global Regional Market Snapshot
6.3. Marker Size, & Forecasts Trend Analysis, 2023 to 2032:
6.4. North America
6.4.1. U.S.
6.4.1.1. Key Country Dynamics
6.4.1.2. Competitive Scenario
6.4.1.3. Regulatory Framework
6.4.1.4. U.S. Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.4.2. Canada
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. Canada Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key Country Dynamics
6.5.1.2. Competitive Scenario
6.5.1.3. Regulatory Framework
6.5.1.4. UK Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.5.2. Germany
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Germany Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.5.3. Spain
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Spain Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. France Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Italy Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.5.6. Denmark
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Denmark Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.5.6.5.
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. Sweden Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework
6.5.8.4. Norway Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key Country Dynamics
6.6.1.2. Competitive Scenario
6.6.1.3. Regulatory Framework
6.6.1.4. Japan Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.6.2. China
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. China Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.6.3. India
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. India Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.6.4. South Korea
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. South Korea Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Thailand Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Competitive Scenario
6.6.6.3. Regulatory Framework
6.6.6.4. Australia Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key Country Dynamics
6.7.1.2. Competitive Scenario
6.7.1.3. Regulatory Framework
6.7.1.4. Brazil Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.7.2. Mexico
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. Mexico Blood Glucose Monitoring Devices Market, 2023 to 2032 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Argentina Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key Country Dynamics
6.8.1.2. Competitive Scenario
6.8.1.3. Regulatory Framework
6.8.1.4. South Africa Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key Country Dynamics
6.8.2.2. Competitive Scenario
6.8.2.3. Regulatory Framework
6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.8.3. UAE
6.8.3.1. Key Country Dynamics
6.8.3.2. Competitive Scenario
6.8.3.3. Regulatory Framework
6.8.3.4. UAE Market Estimates and Forecasts 2023 to 2032 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key Country Dynamics
6.8.4.2. Competitive Scenario
6.8.4.3. Regulatory Framework
6.8.4.4. Kuwait Market Estimates and Forecasts 2023 to 2032 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company /Competition Categorization
7.3. Vendor Landscape
7.3.1. List Of Key Distributors and Channel Partners
7.3.2. Key Customers
7.3.3. Key Company Market Share Analysis, 2023
7.3.4. Thermo Fisher Scientific (Patheon) 
7.3.4.1. Overview
7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.4.3. Product Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Abbott
7.3.5.1. Overview
7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.5.3. Product Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. F. Medtronic plc 
7.3.6.1. Overview
7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.6.3. Product Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. Medtronic plc 
7.3.7.1. Overview
7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.7.3. Product Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Ascensia Diabetes Care Holdings AG
7.3.8.1. Overview
7.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.8.3. Product Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. Ascensia Diabetes Care Holdings AG
7.3.9.1. Overview
7.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.9.3. Product Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Sanofi 
7.3.10.1. Overview
7.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.10.3. Product Benchmarking
7.3.10.4. Strategic Initiatives
7.3.11. Novo Nordisk 
7.3.11.1. Overview
7.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.11.3. Product Benchmarking
7.3.11.4. Strategic Initiatives
7.3.12. Insulet Corporation 
7.3.12.1. Overview
7.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.12.3. Product Benchmarking
7.3.12.4. Strategic Initiatives

7.3.13. Ypsomed Holdings 
7.3.13.1. Overview
7.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.13.3. Product Benchmarking
7.3.13.4. Strategic Initiatives

7.3.13. Glysens Incorporated 
7.3.13.1. Overview
7.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.13.3. Product Benchmarking
7.3.13.4. Strategic Initiatives